"Too little, too late?" Will inhibitors of the hepatitis C virus p7 ion channel ever be used in the clinic?

Future Medicinal Chemistry

Volumn 6, Issue 17, 2014, Pages 1893-1907

  Griffin, Stephen ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ION CHANNEL; PROTEIN INHIBITOR; PROTEIN P7; UNCLASSIFIED DRUG; VIRUS PROTEIN; ANTIVIRUS AGENT; P7 PROTEIN, HEPATITIS C VIRUS;

DRUG POTENCY; DRUG SYNTHESIS; HEPATITIS C; HEPATITIS C VIRUS; NONHUMAN; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; VIRUS INHIBITION; ALLOSTERISM; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; GENETICS; GENOTYPE; HEPACIVIRUS; HUMAN; METABOLISM; MOLECULAR DOCKING; PROTEIN TERTIARY STRUCTURE;

ALLOSTERIC REGULATION; ANTIVIRAL AGENTS; BINDING SITES; DRUG EVALUATION, PRECLINICAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; MOLECULAR DOCKING SIMULATION; PROTEIN STRUCTURE, TERTIARY; VIRAL PROTEINS;

EID: 84919794668     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.14.121     Document Type: Review

References (99)

1. Pawlotsky JM, Chevaliez S, Mchutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 132(5), 1979-1998 (2007
2. Pawlotsky JM. The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending. Gastroenterology 140(3), 746-754 (2011
3. Afdhal N, Reddy KR, Nelson DR et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N. Engl. J. Med. 370(16), 1483-1493 (2014
4. Afdhal N, Zeuzem S, Kwo P et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N. Engl. J. Med. 370(20), 1889-1898 (2014
5. Dhaliwal HS, Nampoothiri RV. Daclatasvir plus sofosbuvir for HCV infection. N. Engl. J. Med. 370(16), 1560 (2014
6. Kowdley KV, Gordon SC, Reddy KR et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N. Engl. J. Med. 370(20), 1879-1888 (2014
7. Lawitz E, Poordad FF, Pang PS et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, Phase 2 trial. Lancet 383(9916), 515-523 (2014
8. Sulkowski MS, Gardiner DF, Rodriguez-Torres M et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N. Engl. J. Med. 370(3), 211-221 (2014
9. Sulkowski MS, Jacobson IM, Nelson DR. Daclatasvir plus sofosbuvir for HCV infection. N. Engl. J. Med. 370(16), 1560-1561 (2014
10. Aghemo A, De Francesco R. New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology 58(1), 428-438 (2013
11. Sakai A, Claire MS, Faulk K et al. The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences. Proc. Natl Acad. Sci. USA 100(20), 11646-11651 (2003
12. Jones CT, Murray CL, Eastman DK, Tassello J, Rice CM. Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. J. Virol. 1(16), 8374-8383 (2007
13. Steinmann E, Penin F, Kallis S, Patel AH, Bartenschlager R, Pietschmann T. Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions. PLoS Pathog. 3(7), e103 (2007
14. Griffin SD, Beales LP, Clarke DS et al. The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine. FEBS Lett. 535(1-3), 34-38 (2003
15. Cook GA, Dawson LA, Tian Y, Opella SJ. Threedimensional structure and interaction studies of hepatitis C virus p7 in 1, 2-dihexanoyl-sn-glycero-3-phosphocholine by solution nuclear magnetic resonance. Biochemistry 52(31), 5295-5303 (2013
16. Foster TL, Thompson GS, Kalverda AP et al. Structureguided design affirms inhibitors of hepatitis C virus p7 as a viable class of antivirals targeting virion release. Hepatology 59(2), 408-422 (2014
17. Ouyang B, Xie S, Berardi MJ et al. Unusual architecture of the p7 channel from hepatitis C virus. Nature 498(7455), 521-525 (2013
18. Lin C, Lindenbach BD, Pragai BM, Mccourt DW, Rice CM. Processing in the hepatitis C virus E2-NS2 region: identification of p7 and two distinct E2-specific products with different C termini. J. Virol. 68(8), 5063-5073 (1994
19. Mizushima H, Hijikata M, Asabe S, Hirota M, Kimura K, Shimotohno K. Two hepatitis C virus glycoprotein E2 products with different C termini. J. Virol. 68(10), 6215-6222 (1994
20. Carrere-Kremer S, Montpellier C, Lorenzo L et al. Regulation of hepatitis C virus polyprotein processing by signal peptidase involves structural determinants at the p7 sequence junctions. J. Biol. Chem. 279(40), 41384-41392 (2004
21. Isherwood BJ, Patel AH. Analysis of the processing and transmembrane topology of the E2p7 protein of hepatitis C virus. J. Gen. Virol. 86, 667-676 (2005
22. Chandler DE, Penin F, Schulten K, Chipot C. The p7 protein of hepatitis c virus forms structurally plastic, minimalist ion channels. PLoS. Comput. Biol. 8(9), e1002702 (2012
23. Carrere-Kremer S, Montpellier-Pala C, Cocquerel L, Wychowski C, Penin F, Dubuisson J. Subcellular localization and topology of the p7 polypeptide of hepatitis C virus. J. Virol. 76(8), 3720-3730 (2002
24. Pavlovic D, Neville DC, Argaud O et al. The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives. Proc. Natl Acad. Sci. USA 100(10), 6104-6108 (2003
25. Premkumar A, Wilson L, Ewart GD, Gage PW. Cationselective ion channels formed by p7 of hepatitis C virus are blocked by hexamethylene amiloride. FEBS Lett. 557(1-3), 99-103 (2004
26. Clarke D, Griffin S, Beales L et al. Evidence for the formation of a heptameric ion channel complex by the hepatitis C virus p7 protein in vitro. J. Biol. Chem. 281(48), 37057-37068 (2006
27. Gervais C, Do F, Cantin A et al. Development and validation of a high-throughput screening assay for the hepatitis C virus p7 viroporin. J. Biomol. Screen 16(3), 363-369 (2011
28. Kurtz S, Luo G, Hahnenberger KM et al. Growth impairment resulting from expression of influenza virus M2 protein in Saccharomyces cerevisiae: identification of a novel inhibitor of influenza virus. Antimicrob. Agents Chemother. (Bethesda) 39(10), 2204-2209 (1995
29. Luik P, Chew C, Aittoniemi J et al. The 3-dimensional structure of a hepatitis C virus p7 ion channel by electron microscopy. Proc. Natl Acad. Sci. USA 106(31), 12712-12716 (2009
30. Steinmann E, Whitfield T, Kallis S et al. Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus. Hepatology 46(2), 330-338 (2007
31. Lamarre D, Anderson PC, Bailey M et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426(6963), 186-189 (2003
32. Patargias G, Zitzmann N, Dwek R, Fischer WB. Protein-protein interactions: modeling the hepatitis C virus ion channel p7. J. Med. Chem. 49(2), 648-655 (2006
33. Griffin SD, Harvey R, Clarke DS, Barclay WS, Harris M, Rowlands DJ. A conserved basic loop in hepatitis C virus p7 protein is required for amantadine-sensitive ion channel activity in mammalian cells but is dispensable for localization to mitochondria. J. Gen. Virol. 85(Pt 2), 451-461 (2004
34. Tedbury P, Welbourn S, Pause A, King B, Griffin S, Harris M. The subcellular localization of the hepatitis C virus non-structural protein NS2 is regulated by an ion channelindependent function of the p7 protein. J. Gen. Virol. 92(Pt 4), 819-830 (2011).
35. Stapleford KA, Lindenbach BD. Hepatitis C virus NS2 coordinates virus particle assembly through physical interactions with the E1-E2 glycoprotein and NS3-NS4A enzyme complexes. J. Virol. 85(4), 1706-1717 (2011
36. Popescu CI, Callens N, Trinel D et al. NS2 protein of hepatitis C virus interacts with structural and non-structural proteins towards virus assembly. PLoS Pathog. 7(2), e1001278 (2011
37. Ma Y, Anantpadma M, Timpe JM et al. Hepatitis C virus NS2 protein serves as a scaffold for virus assembly by interacting with both structural and nonstructural proteins. J. Virol. 85(1), 86-97 (2011
38. Jirasko V, Montserret R, Lee JY et al. Structural and functional studies of nonstructural protein 2 of the hepatitis C virus reveal its key role as organizer of virion assembly. PLoS Pathog. 6(12), e1001233 (2010
39. Jirasko V, Montserret R, Appel N et al. Structural and functional characterization of nonstructural protein 2 for its role in hepatitis C virus assembly. J. Biol. Chem. 283(42), 28546-28562 (2008
40. Gentzsch J, Brohm C, Steinmann E et al Hepatitis c virus p7 is critical for capsid assembly and envelopment. PLoS Pathog. 9(5), e1003355 (2013
41. Wozniak AL, Griffin S, Rowlands D et al. Intracellular proton conductance of the hepatitis C virus p7 protein and its contribution to infectious virus production. PLoS Pathog. 6(9), e1001087 (2010
42. Atkins E, Tatineni R, Li H, Gretch D, Harris M, Griffin S. The stability of secreted, acid-labile H77/JFH-1 hepatitis C virus (HCV) particles is altered by patient isolate genotype 1a p7 sequences. Virology 448, 117-124 (2014
43. Meredith LW, Zitzmann N, Mckeating JA. Differential effect of p7 inhibitors on hepatitis C virus cell-to-cell transmission. Antiviral Res. 100(3), 636-639 (2013
44. Davies WL, Grunert RR, Haff RF et al. Antiviral activity of 1-adamantanamine (amantadine). Science 144(3620), 862-863 (1964
45. Sabin AB. Amantadine hydrochloride. Analysis of data related to its proposed use for prevention of A2 influenza virus disease in human beings. JAMA 200(11), 943-950 (1967
46. Dawkins AT Jr, Gallager LR, Togo Y, Hornick RB, Harris BA. Studies on induced influenza in man. II. Double-blind study designed to assess the prophylactic efficacy of an analogue of amantadine hydrochloride. JAMA 203(13), 1095-1099 (1968
47. Togo Y, Hornick RB, Dawkins AT Jr. Studies on induced influenza in man. I. Double-blind studies designed to assess prophylactic efficacy of amantadine hydrochloride against a2/Rockville/1/65 strain. JAMA 203(13), 1089-1094 (1968
48. Wingfield WL, Pollack D, Grunert RR. Therapeutic efficacy of amantadine HCl and rimantadine HCl in naturally occurring influenza A2 respiratory illness in man. N. Engl. J. Med. 281(11), 579-584 (1969
49. Hay AJ, Wolstenholme AJ, Skehel JJ, Smith MH. The molecular basis of the specific anti-influenza action of amantadine. EMBO J. 4(11), 3021-3024 (1985
50. Duff KC, Ashley RH. The transmembrane domain of influenza A M2 protein forms amantadine-sensitive proton channels in planar lipid bilayers. Virology 190(1), 485-489 (1992
51. Pinto LH, Holsinger LJ, Lamb RA. Influenza virus M2 protein has ion channel activity. Cell 69(3), 517-528 (1992
52. Schnell JR, Chou JJ. Structure and mechanism of the M2 proton channel of influenza A virus. Nature 451(7178), 591-595 (2008
53. Stouffer AL, Acharya R, Salom D et al. Structural basis for the function and inhibition of an influenza virus proton channel. Nature 451(7178), 596-599 (2008
54. Wang J, Wu Y, Ma C et al. Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus. Proc. Natl Acad. Sci. USA 110(4), 1315-1320 (2013
55. Balgi AD, Wang J, Cheng DY et al. Inhibitors of the influenza A virus M2 proton channel discovered using a highthroughput yeast growth restoration assay. PLoS ONE 8(2), e55271 (2013
56. Griffin S, Stgelais C, Owsianka AM, Patel AH, Rowlands D, Harris M. Genotype-dependent sensitivity of hepatitis C virus to inhibitors of the p7 ion channel. Hepatology 48(6), 1779-1790 (2008
57. Gottwein JM, Jensen TB, Mathiesen CK et al. Development and application of hepatitis C reporter viruses with genotype 1 to 7 core-nonstructural protein 2 (NS2) expressing fluorescent proteins or luciferase in modified JFH1 NS5A. J. Virol. 85(17), 8913-8928 (2011
58. Foster TL, Verow M, Wozniak AL et al. Resistance mutations define specific antiviral effects for inhibitors of the hepatitis C virus p7 ion channel. Hepatology 54(1), 79-90 (2011
59. Mihm U, Grigorian N, Welsch C et al. Amino acid variations in hepatitis C virus p7 and sensitivity to antiviral combination therapy with amantadine in chronic hepatitis C. Antivir. Ther. 11(4), 507-519 (2006
60. Whitfield T, Miles AJ, Scheinost JC et al. The influence of different lipid environments on the structure and function of the hepatitis C virus p7 ion channel protein. Mol. Membr. Biol. (2011
61. Stgelais C, Foster TL, Verow M et al. Determinants of hepatitis C virus p7 ion channel function and drug sensitivity identified in vitro. J. Virol. 83(16), 7970-7981 (2009
62. Saint N, Montserret R, Chipot C, Penin F. Structural and functional analysis of the HCV p7 protein. Methods Mol. Biol. 510, 125-143 (2009
63. Montserret R, Saint N, Vanbelle C et al. NMR structure and ion channel activity of the p7 protein from hepatitis C virus. J. Biol. Chem. 285(41), 31446-31461 (2010
64. Cook GA, Opella SJ. Secondary structure, dynamics, and architecture of the p7 membrane protein from hepatitis C virus by NMR spectroscopy. Biochim. Biophys. Acta 1808(6), 1448-1453 (2011
65. Cook GA, Opella SJ. NMR studies of p7 protein from hepatitis C virus. Eur. Biophys. J. 39(7), 1097-1104 (2010
66. Chew CF, Vijayan R, Chang J, Zitzmann N, Biggin PC. Determination of pore-lining residues in the hepatitis C virus p7 protein. Biophys. J. 96(2), L10-12 (2009
67. Luscombe CA, Huang Z, Murray MG, Miller M, Wilkinson J, Ewart GD. A novel Hepatitis C virus p7 ion channel inhibitor, BIT225, inhibits bovine viral diarrhea virus in vitro and shows synergism with recombinant interferon-alpha-2b and nucleoside analogues. Antiviral Res. 86(2), 144-153 (2010
68. Ewart GD, Sutherland T, Gage PW, Cox GB. The Vpu protein of human immunodeficiency virus type 1 forms cation-selective ion channels. J. Virol. 70(10), 7108-7115 (1996
69. Conference reports for NATAP: HepDART 2011
70. Largo E, Gladue DP, Huarte N, Borca MV, Nieva JL. Poreforming activity of pestivirus p7 in a minimal model system supports genus-specific viroporin function. Antiviral Res. 101, 30-36 (2014
71. Gladue DP, Holinka LG, Largo E et al. Classical swine fever virus p7 protein is a viroporin involved in virulence in swine. J. Virol. 86(12), 6778-6791 (2012
72. Khoury G, Ewart G, Luscombe C, Miller M, Wilkinson J. Antiviral efficacy of the novel compound BIT225 against HIV-1 release from human macrophages. Antimicrob. Agents Chemother. (Bethesda) 54(2), 835-845 (2010
73. Gan SW, Surya W, Vararattanavech A, Torres J. Two different conformations in hepatitis C virus p7 protein account for proton transport and dye release. PLoS ONE 9(1), e78494 (2014
74. Wetherill LF, Holmes KK, Verow M et al. High-risk human papillomavirus E5 oncoprotein displays channel-forming activity sensitive to small-molecule inhibitors. J. Virol. 86(9), 5341-5351 (2012
75. Agirre A, Barco A, Carrasco L, Nieva JL. Viroporin-mediated membrane permeabilization. Pore formation by nonstructural poliovirus 2B protein. J. Biol. Chem. 277(43), 40434-40441 (2002
76. Carter SD, Dent KC, Atkins E et al. Direct visualization of the small hydrophobic protein of human respiratory syncytial virus reveals the structural basis for membrane permeability. FEBS Lett. 584(13), 2786-2790 (2010
77. Agirre A, Lorizate M, Nir S, Nieva JL. Poliovirus 2b insertion into lipid monolayers and pore formation in vesicles modulated by anionic phospholipids. Biochim. Biophys. Acta 1778(11), 2621-2626 (2008
78. Ouyang B, Chou JJ. The minimalist architectures of viroporins and their therapeutic implications. Biochim. Biophys. Acta 1838(4), 1058-1067 (2014
79. Manns MP, Von Hahn T. Novel therapies for hepatitis C - one pill fits all?. Nat. Rev. Drug Discov. 12(8), 595-610 (2013
80. Zeuzem S, Dusheiko GM, Salupere R et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N. Engl. J. Med. 370(21), 1993-2001 (2014
81. Suzuki Y, Ikeda K, Suzuki F et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J. Hepatol. 58(4), 655-662 (2013
82. Manns MP, Vierling JM, Bacon BR et al. The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis. Gastroenterology 147(2), 366-376 (2014
83. Summa V, Ludmerer SW, Mccauley JA et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob. Agents Chemother. 56(8), 4161-4167 (2012
84. Mccown MF, Rajyaguru S, Le Pogam S et al. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob. Agents Chemother. 52(5), 1604-1612 (2008
85. Fridell RA, Wang C, Sun JH et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 54(6), 1924-1935 (2011
86. Mcphee F, Hernandez D, Yu F et al. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology 58(3), 902-911 (2013
87. Ludmerer SW, Graham DJ, Boots E et al. Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. Antimicrob. Agents Chemother. 49(5), 2059-2069 (2005
88. Conference Reports for NATAP: EASL 48th Annual Meeting. www.natap.org/2013/EASL/EASL-15.htm 89 Flisiak R, Feinman SV, Jablkowski M et al. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology 49(5), 1460-1468 (2009
89. Paeshuyse J, Kaul A, De Clercq E et al. The nonimmunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 43(4), 761-770 (2006
90. Patel H, Heathcote EJ. Sustained virological response with 29 days of Debio 025 monotherapy in hepatitis C virus genotype 3. Gut 60(6), 879 (2011
91. Zhu H, Wong-Staal F, Lee H et al. Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals. J. Infect Dis. 205(4), 656-662 (2012
92. Vausselin T, Calland N, Belouzard S et al. The antimalarial ferroquine is an inhibitor of hepatitis C virus. Hepatology 58(1), 86-97 (2013
93. Einav S, Gerber D, Bryson PD et al. Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis. Nat. Biotechnol. 26(9), 1019-1027 (2008
94. Rai R, Deval J. New opportunities in anti-hepatitis C virus drug discovery: Targeting NS4B. Antiviral Res. 90(2), 93-101 (2011
95. Esser-Nobis K, Romero-Brey I, Ganten TM et al. Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B. Hepatology 57(3), 953-963 (2013
96. Deltenre P, Henrion J, Canva V et al. Evaluation of amantadine in chronic hepatitis C: a meta-analysis. J. Hepatol. 41(3), 462-473 (2004
97. Mangia A, Leandro G, Helbling B et al. Combination therapy with amantadine and interferon in naive patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials. J. Hepatol. 40(3), 478-483 (2004
98. Maynard M, Pradat P, Bailly F et al. Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies (ANRS HC 03 BITRI). J. Hepatol. 44(3), 484-490 (2006
99. WHO issues its first Hepatitis C treatment guidelines. www.who.int/mediacentre/news/releases/2014/hepatitisguidelines/en